• The current treatments of depression are based on the “monoamine hypothesis” which claims that depression is caused by a monoamine dysfunction in the brain.
    Today, growing interest has shifted to the reactivation of a juvenile-like plasticity in the brain for the treatment of depression. The reason for this new focus comes from the ability of monoamine oxidase inhibitors and tricyclic antidepressants to rapidly increase monoamine transmission without inducing immediate mood-enhancing properties.

    Neurofit proposes different animal and cellular models to evaluate the efficiency of your compounds following these different hypotheses.